| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_ac517959983f146a11e2cd94417cc64a
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_9df89b4809314b31e3d3ce396108952e
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_47f079fed01315e7f0429c70e359a9b7
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_3f984e52dbc9713e08be56a4fee2d489 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-1658
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-1652
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-1635
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-5084 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-209
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2077
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-10 |
| classificationIPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-50
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-16 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-24
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-48
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-20
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-22
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K49-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K45-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P3-10 |
| filingDate |
2003-07-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4cecab8aa14475f260cd1c6a13043798
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_520642b918f96720cfd8b54ca6be3bd2
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_445434097606ef421a0dc4e43627612a |
| publicationDate |
2005-08-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
EP-1558220-A1 |
| titleOfInvention |
Oral compositions for treatment of diseases |
| abstract |
This invention describes the use of pharmaceutical compositions, which comprises three components of which at least one is a slow release therapeutic agent. Such useful compositions are applicable for the treatment of humans suffering from diabetic, hypertensive, cardiovascular, hyperlipidemic conditions and their associated disorders thereof. Combination therapy has the advantages of better patient compliance; better therapeutic efficacy coupled with a reduction in the dose for some of the individual therapeutic agent(s) in the combination. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2017100359-A1 |
| priorityDate |
2003-07-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |